KRAS mutation status critically determines the clinical outcome of patients with KMT2A-rearranged acute myeloid leukemia. Wu Y, Yuan X, Lai X, Liu L, et al. Cancer 2025;131:e35941.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Wu Y, Yuan X, Lai X, Liu L, et al. KRAS mutation status critically determines the clinical outcome of patients with KMT2A-rearranged acute myeloid leukemia. Cancer 2025;131:e35941.
PMID: 40530668